Ondine presents new efficacy data against MRSA
19 October 2022
Ondine Biomedical Inc.
("Ondine Biomedical", "Ondine" or the "Company")
Ondine presents new efficacy data against MRSA
· Photodisinfection technology shows great promise as a new method for fighting drug-resistant infections amidst rising rates of antimicrobial resistance.
Ondine Biomedical, Inc. (LON:OBI): Canadian life sciences company, Ondine Biomedical, presented new research at the Infection Prevention Society Conference (IPS) in Bournemouth, UK (17th October) showing that its photodisinfection technology is highly effective against clinical MRSA isolates exhibiting multidrug-resistance. With more than a quarter of people colonized with Staphylococcus aureus in the nose and some of these carrying the MRSA type, there remains an unmet need for new therapies. Few new antibiotics are under development and alternative means of killing drug-resistant infections must be found. Light-activated compounds may provide an answer.
This new research was conducted using 100 recent multidrug-resistant Staphylococcus aureus (MRSA) clinical isolates obtained from patients presenting to a large tertiary care hospital in Vancouver, British Columbia. Each isolate was selected for resistance to one or more major classes of antibiotics in widespread use today, and then subjected to Steriwave photodisinfection in vitro. The study found that the photodisinfection treatment eliminated more than 99.9% of each isolate in only 60 seconds, irrespective of the isolate's antibiotic resistance.
Jason Hickok, Ondine Biomedical's VP, Medical and Clinical Affairs said:
"Antibiotic resistance is one of the most dangerous developments in clinical medicine. Over 200 Americans and 78 Britons die each day from an untreatable hospital-acquired infection, and hundreds of patients more suffer from comorbidities and disfigurements of lifesaving revision surgeries and associated treatment. When we lose the antibiotic, we return to a way of life almost a century ago, where a scratched knee, or a minor burn could prove lethal. This research demonstrates the power of Steriwave photodisinfection, a modern photonic solution to topical disinfection without using antibiotics, without engendering resistance, and without causing pain or side effects to the patient."
Photodisinfection, also known as antimicrobial photodisinfection therapy (aPDT), combines a photosensitive compound with a specific wavelength of light. When illuminated, the photosensitiser forms reactive oxygen species that are highly destructive to bacteria, viruses, and fungi. Since photodisinfection is not an antibiotic it does not cause antibiotic resistance, making it an ideal technology to avoid overuse of antibiotics.
Pathogens that have developed resistance to antimicrobials are a significant global health challenge, and new solutions are desperately needed to combat them. An analysis published in the Lancet in 2022 found that 1.27 million deaths in 2019 were the direct result of drug-resistant bacterial infections, exceeding the number of deaths from malaria or AIDS.[i]
Ondine's nasal photodisinfection technology has a CE mark for use in the EU and is approved in Canada and number of other countries, including the UK. In the US, Ondine recently completed a Phase 2 trial, forming part of the Company's US FDA regulatory application.
A copy of the full research poster "Antimicrobial Photodynamic Therapy Against Clinical Isolates of MRSA" can be downloaded here.
|
Ondine Biomedical Inc. |
|
|
Angelika Vance, Corporate Communications |
+001 (1) 604 838 2702 |
|
|
|
|
Strand Hanson Limited (Nominated and Financial Adviser) |
|
|
James Harris, James Dance, Richard Johnson |
+44 (0) 20 7409 3494 |
|
|
|
|
RBC Capital Markets |
|
|
Rupert Walford, Kathryn Deegan |
+44 (0) 20 7653 4000 |
|
|
|
|
Singer Capital Markets |
|
|
Aubrey Powell, Asha Chotai |
+44 (0)20 7496 3000 |
|
|
|
|
Vane Percy & Roberts (Media Contact) |
|
|
Simon Vane Percy, Amanda Bernard |
+44 (0) 77 1000 5910 |
About the Infection Prevention Society Annual Conference
The IPS annual conference is the largest infection prevention and control meeting in the UK and attracts over 1,000 renowned infection prevention experts. The conference is relevant to healthcare delegates, as the issue of infection prevention is becoming increasingly important, as well as to many industry sectors from catering to hospitality and from pharmacy to dentistry. With its high-profile speakers and prestigious reputation within the infection control sector, the conference showcases abstracts, posters and lectures on the latest advances in infection prevention. More information can be found at www.ips.uk.net.
About Nasal Photodisinfection
Ondine's nasal photodisinfection comprises a two-step process: the application of a proprietary light-activated solution to each nostril using a nasal swab, followed by illumination of the area with a specific wavelength of laser light for less than five minutes. The photodisinfection process works by light exciting the photodynamic solution, causing an oxidative burst that is lethal to pathogens. Watch video here: www.ondinebio.com/technology . A key benefit of this approach, unlike with antibiotics, is that pathogens do not develop resistance to the therapy. Photodisinfection is also known in the scientific community as antimicrobial photodynamic therapy (aPDT).
Ondine's nasal photodisinfection has a CE mark for use in the EU and is approved in Canada and several other countries, including the UK, under the name Steriwave ™ . In the US, it has received Qualified Infectious Disease Product designation and Fast Track status from the FDA and is currently undergoing clinical trials for US regulatory approval.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as sinusitis, ventilator-associated pneumonia, burns, and other indications.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund